Codexis, Inc. (CDXS) |
| 1.6611 -0.019 (-1.13%) 08-26 10:44 |
| Open: | 1.68 |
| High: | 1.69 |
| Low: | 1.65 |
| Volume: | 154,851 |
| Market Cap: | 179(M) |
| PE Ratio: | -4.89 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.06 |
| Resistance 1: | 1.80 |
| Pivot price: | 1.58 |
| Support 1: | 1.38 |
| Support 2: | 1.15 |
| 52w High: | 2.98 |
| 52w Low: | 0.96 |
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
| EPS | -0.330 |
| Book Value | 0.360 |
| PEG Ratio | 13.53 |
| Gross Profit | 0.172 |
| Profit Margin (%) | -39.55 |
| Operating Margin (%) | -75.29 |
| Return on Assets (ttm) | -11.7 |
| Return on Equity (ttm) | -69.4 |
Mon, 24 Aug 2026
Codexis (CDXS) Financial Results: The Available Earnings Metric Delivers a Beat in the Latest Reading; Session Move - vinanet.vn
Sat, 22 Aug 2026
Q4 2025 Codexis Inc Earnings Call Transcript - GuruFocus
Fri, 21 Aug 2026
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates - Eastern Progress
Thu, 13 Aug 2026
Codexis (CDXS) investor Laurence Lytton discloses 5.2% beneficial stake in shares - Stock Titan
Tue, 11 Aug 2026
Codexis: Q2 Earnings Snapshot - 10TV
Tue, 04 Aug 2026
Codexis, Inc. Revenue Breakdown – NASDAQ:CDXS - TradingView
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |